Division of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Makhanda 6139, South Africa.
Int J Mol Sci. 2022 Oct 30;23(21):13223. doi: 10.3390/ijms232113223.
Opportunities for developing innovative and intelligent drug delivery technologies by targeting the endocannabinoid system are becoming more apparent. This review provides an overview of strategies to develop targeted drug delivery using the endocannabinoid system (ECS). Recent advances in endocannabinoid system targeting showcase enhanced pharmaceutical therapy specificity while minimizing undesirable side effects and overcoming formulation challenges associated with cannabinoids. This review identifies advances in targeted drug delivery technologies that may permit access to the full pharmacotherapeutic potential of the ECS. The design of optimized nanocarriers that target specific tissues can be improved by understanding the nature of the signaling pathways, distribution in the mammalian body, receptor structure, and enzymatic degradation of the ECS. A closer look at ligand-receptor complexes, endocannabinoid tone, tissue distribution, and G-protein activity leads to a better understanding of the potential of the ECS toolkit for therapeutics. The signal transduction pathways examine the modulation of downstream effector proteins, desensitization, signaling cascades, and biased signaling. An in-depth and overall view of the targeted system is achieved through homology modeling where mutagenesis and ligand binding examine the binding site and allow sequence analysis and the formation of libraries for molecular docking and molecular dynamic simulations. Internalization routes exploring receptor-mediated endocytosis and lipid rafts are also considered for explicit signaling. Furthermore, the review highlights nanotechnology and surface modification aspects as a possible future approach for specific targeting.
通过靶向内源性大麻素系统来开发创新型智能药物输送技术的机会越来越明显。本文综述了利用内源性大麻素系统(ECS)开发靶向药物输送的策略。最近在内源性大麻素系统靶向方面的进展展示了增强药物治疗的特异性,同时最大限度地减少不良副作用,并克服与大麻素相关的制剂挑战。本文确定了靶向药物输送技术的进展,这些进展可能允许充分利用 ECS 的药物治疗潜力。通过了解信号通路的性质、在哺乳动物体内的分布、受体结构和 ECS 的酶降解,可优化靶向特定组织的纳米载体的设计。更深入地研究配体-受体复合物、内源性大麻素张力、组织分布和 G 蛋白活性,有助于更好地理解 ECS 工具包在治疗中的潜力。信号转导途径检查下游效应蛋白的调节、脱敏、信号级联和偏向信号。通过同源建模实现对靶向系统的深入全面的了解,其中突变和配体结合检查结合位点,并允许进行序列分析和形成分子对接和分子动力学模拟的库。还考虑了受体介导的内吞作用和脂筏的内化途径,以进行明确的信号传递。此外,该综述强调了纳米技术和表面修饰方面作为特定靶向的可能未来方法。